QPS Holdings and Hepregen Corporation Announce Commercial Partnership
News May 30, 2013
QPS Holdings, LLC and Hepregen Corporation have announced the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies.
QPS expects to begin offering metabolite identification, profiling, and clearance studies to North American customers before the end of June, and to European customers in the third calendar quarter of this year using HepatoPacTM products. The North American services will be offered from its well established DMPK department in Newark, Delaware, and its newly established DMPK Hepatic Biosciences division based at the Hamner Institutes in Research Triangle Park, North Carolina, using rat, dog, monkey and human HepatoPacTM products.
“Our ability to offer services utilizing Hepregen’s next-generation product portfolio is another demonstration of the QPS commitment to enhancing its leadership position in the ADME field, providing cutting-edge, liver-based in vitro services to the pharmaceutical and agrochemical industry,” stated Dr. Zamas Lam, QPS Senior Vice President of Preclinical Development.
“QPS brings an extraordinary capability and expertise in bioanalytical technology and hepatic cell biology to our partnership and a strong commitment to a progressive vision in the growing field of hepatic sciences,” stated Dr. Vincent Zurawski, Hepregen’s Chief Executive. “Moreover, QPS is an exceptionally well-managed company, as demonstrated by its outstanding record of growth in the last five years. We are extremely pleased to be engaged with such a strong partner in this paradigm-shifting endeavor,” added Dr. Zurawski.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE